Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALVAC NY ESO-1
- Development stage
- Unknown
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
ALVAC NY ESO-1 is a cancer vaccine designed to stimulate the immune system to recognize and attack tumor cells expressing the cancer-testis antigen NY-ESO-1. The vaccine uses a recombinant canarypox virus (ALVAC) as a vector to deliver the gene encoding the full-length NY-ESO-1 protein. Upon administration, it aims to induce a cytotoxic T lymphocyte (CTL) response against cancer cells that express NY-ESO-1, potentially inhibiting tumor growth and proliferation. This approach leverages both cellular and humoral immunity for antitumor effects. The primary indications under investigation include metastatic melanoma and renal cell carcinoma[1][6].
- Other names
- ALVAC NY ESO-1 vaccineALVAC ESO-1 vaccine
02
Targets
MHC-NY-ESO-1 (Major Histocompatibility Complex-NY-ESO-1 peptide complex)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on ALVAC NY ESO-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALVAC NY ESO-1.